<DOC>
	<DOC>NCT02948829</DOC>
	<brief_summary>The purpose of this study is to assess the cellular immune responses following 2 doses of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.</brief_summary>
	<brief_title>Safety and Immunogenicity of Takeda's TDV in Healthy Children</brief_title>
	<detailed_description>The vaccine being tested in this study is TDV. This study will look at cellular immune responses following TDV vaccination in dengue endemic regions. The study will enroll approximately 200 participants. Participants will receive: • TDV 0.5 mL subcutaneous (SC) injection All participants will receive 2-dose schedule of TDV by SC injection into the upper arm at Day 1 (Month 0) and at Day 90 (Month 3). This multi-center trial will be conducted in Panama and the Philippines. The overall time to participate in this study is approximately 3 years 4 months. Participants will make multiple visits to the clinic and will be contacted at least every week for the entire study duration post first injection.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. Is aged 4 to 16 years, inclusive (Latin America) or 4 to 8 years, inclusive (Asia). 2. Are in good health at the time of entry into the study as determined by medical history, physical examination (including vital signs), and clinical judgment of the investigator. 1. Febrile illness (body temperature ≥38°C) or moderate or severe acute illness or infection at the time of enrolment. 2. History or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose an additional risk to the participant due to participation in the study. 3. Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccines within 28 days after Day 1 (Month 0). 4. Previous participation in any clinical study of a dengue candidate vaccine, or previous receipt of any dengue vaccines (investigational or licensed).</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>